BioSpace News Archive

SQI Diagnostics Inc. today announces that it has entered into a new consulting agreement with Looking Glass Capital Consultants.

iCAD, Inc. today announced that it will release financial results for the fourth quarter and year ended December 31, 2022, after the market close, and host a conference call at 4:30 PM ET on Tuesday, March 28, 2023.

Vivasure Medical ® Limited today announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational Device Exemption (IDE) to advance the company’s PATCH Clinical Study, a multi-center, single-arm, pivotal study evaluating the safety and effectiveness of the Vivasure PerQseal® Closure Device System.

Myomo, Inc. today announced financial results for the three months and full year ended December, 31, 2022.

Champions Oncology, Inc. will report its financial and operational results for the third quarter ended January 31, 2023, on Wednesday, March 15, 2023, after market close.

Medtronic plc, a global leader in healthcare technology, has been recognized by Ethisphere, a leader in defining and advancing the standards of ethical business practices, as one of the 2023 World’s Most Ethical Companies.

Gestalt Diagnostics Inc. and Pramana, Inc. announced a strategic collaboration to provide an AI-powered, end-to-end digital pathology platform for laboratories, health systems and academic medical centers.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB.

American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRF) (the “Company” or “Aires”) is pleased to announce that it has been successful in its application to the Ontario Securities Commission, Alberta Securities Commission and British Columbia Securities Commission (collectively, the “Commissions”) to revoke the failure-to-file cease trade order issued by the Ontario Securities Commission on May 6, 2022 (the “CTO”).

Celmatix Inc., the leading women’s health biotech focused on ovarian biology, today announced findings from its long-term collaboration with researchers from the University of Oxford and 24 other institutions to decode the genetic basis of endometriosis, a condition that globally impacts 1 in 10 women*